Preoperative treatment with metyrapone in patients with cushing’s syndrome due to adrenal adenoma. a pilot prospective study by Puglisi, S. et al.
7:11 1227–1235S Puglisi et al. Presurgical metyrapone in 
adrenal Cushing
RESEARCH
Preoperative treatment with metyrapone in 
patients with Cushing’s syndrome due to 
adrenal adenoma: a pilot prospective study
Soraya Puglisi1, Paola Perotti1, Mattia Barbot2, Paolo Cosio1, Carla Scaroni2, Antonio Stigliano3, Pina Lardo3, 
Valentina Morelli4, Elisa Polledri5, Iacopo Chiodini4, Giuseppe Reimondo1, Anna Pia1 and Massimo Terzolo1
1Internal Medicine 1, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
2Endocrinology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
3Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital University of Rome, Rome, Italy
4Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan and Fondazione IRCCS Ca’ Granda, Ospedale Maggiore 
Policlinico, Milano, Italy
5Department of Clinical Sciences and Community Health, Laboratory of Toxicology, University of Milan and Fondazione IRCCS Ca’ Granda,  
Ospedale Maggiore Policlinico, Milan, Italy
Correspondence should be addressed to G Reimondo: giuseppe.reimondo@unito.it
Abstract
Objective: Metyrapone has been approved for the treatment of patients with Cushing’s 
syndrome (CS), but only few retrospective clinical studies are available. The aim of our 
study was the prospective assessment of metyrapone as pre-operative treatment.
Design and methods: Before adrenalectomy, seven patients with ACTH-independent 
CS due to adrenal adenoma were prospectively treated with metyrapone for 3 months 
in three tertiary academic centers, with endocrine work-up and clinical evaluation at 
screening and at predefined evaluation time points (Days 14, 31, 48, 65, 82).
Results: In all patients, UFC levels decreased up to normal range from baseline to Day 
82 (609 (188–1476) vs 69 (28–152) nmol/24 h, P < 0.02), with a reduction of serum and 
salivary cortisol levels, and no significant increase of plasma ACTH and serum DHEAS 
levels. Clinical improvement was reported on quality of life (+16.7 (+4.2; +52.00) 
points, P < 0.04) and pressure control (systolic pressure, −25 (−52; −10) mmHg, P < 0.01; 
diastolic pressure, −16 (−50; +2 mmHg), P < 0.03). No significant change in weight, 
electrolytes, glycemic and lipid profile was reported. Although in women a significant 
increase of testosterone and androstenedione was reported, no worsening of clinical 
hyperandrogenism was observed. All drug-related adverse events (nausea, fatigue, low 
grade fever, edema of lower limbs and facial rash) were grade 1 or 2 and generally 
transient.
Conclusions: This prospective pilot study demonstrated that metyrapone is effective 
in normalizing biochemical and clinical parameters in patients with CS due to adrenal 
adenoma before surgical intervention, with minimal side effects.
Introduction
Cushing’s syndrome (CS) is a condition of endogenous 
hypercortisolism caused by different pathological entities 
that is classified in two variants: (i) ACTH-dependent CS, 
due to a corticotroph pituitary adenoma or an ectopic 
tumor; (ii) ACTH-independent CS, due to a primary adrenal 
process (tumor or hyperplasia). Whatever the cause, CS is 
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associated with a huge burden of metabolic complications 
(hyperglycemia, dyslipidemia), cardiovascular and 
cerebrovascular diseases (hypertension, coronary artery 
disease, heart failure, stroke, thromboembolic events), 
increased susceptibility to infections and mood disorders. 
Therefore, CS is characterized by impaired quality of life 
(1) and increased mortality, with a reported standard 
mortality ratio between 2.0 and 4.0 (2). Because of 
these clinical consequences, CS requires a prompt and 
definitive resolution since the duration of exposure to 
cortisol excess is a factor portending a worse prognosis (3). 
Surgery is the mainstay of treatment. If surgery fails, or 
is unfeasible, medical treatment can temporarily control 
excessive cortisol production and ameliorate its clinical 
manifestations.
The inhibitors of steroidogenesis are the most used 
drugs to suppress cortisol secretion (4). In particular, 
metyrapone, which affects cortisol secretion by inhibiting 
the 11β-hydroxylase enzyme (CYP11B1) (5, 6), has a solid 
reputation of efficacy and entered clinical use since his 
introduction in 1958 (7); however, the drug has never 
been studied prospectively. Retrospective studies have 
shown that metyrapone is effective in promptly reducing 
cortisol levels. Cortisol dropped within target levels 
after 48–72 h from initiation of treatment with no later 
escape (8, 9). Adverse effects associated to treatment 
were either directly related to the drug intake (nausea, 
vomiting, dizziness, sedation, headache) or secondary to 
the metyrapone-induced alteration of steroid synthesis 
(hirsutism, hypertension) (8, 9).
In patients with ACTH-dependent CS, the block 
of CYP11B1 results in a compensatory rise of pituitary 
ACTH secretion that may lead to accumulation of 
steroid precursors with weak mineralocorticoid activity, 
potentially producing increased blood pressure, edema 
and hypokalemia. Moreover, the treatment leads to a shift 
of steroidogenesis toward the androgen pathway that 
may result in hirsutism and acne in women. However, in 
ACTH-independent CS, the compensatory rise in ACTH 
might not occur because ACTH secretion is chronically 
suppressed by autonomous cortisol secretion, and this 
may ameliorate the safety profile.
We hypothesized that metyrapone could be a perfectly 
suitable drug for a preoperative treatment of patients with 
ACTH-independent CS, since the fast action of the drug 
may allow a prompt improvement of clinical features 
of CS with a presumably favorable safety profile due to 
suppressed ACTH secretion in such patients. Therefore, 
we designed a prospective open-label pilot study of 
a short course of metyrapone treatment to improve 
patient’s conditions and quality of life in preparation to 
adrenalectomy.
Subjects and methods
Patients
For the purpose of this study, we enrolled prospectively 
seven consecutive patients with ACTH-independent CS 
due to an adrenal adenoma scheduled for adrenalectomy, 
who were referred to three tertiary academic centers (San 
Luigi Gonzaga Hospital – University of Turin; University 
Hospital of Padova; Sant’Andrea Hospital – Sapienza 
University of Rome), between March 2014 and February 
2016. All patients presented with a clear phenotype of 
CS and none of the tumors was detected serendipitously. 
They were two men and five women, aged 30–66  years 
(median 40  years). Inclusion criteria for the study were 
age ≥18 years, confirmed diagnosis of ACTH-independent 
CS (validated by all the following criteria: (i) two 24-h 
urinary collections for urinary free cortisol (UFC) both 
>1.5 times the upper normal value, within 2  weeks 
prior to enrollment; (ii) ACTH plasma levels lower 
than the normal range; (iii) serum cortisol following a 
1 mg dexamethasone suppression test (DST) >138 nmol/L 
(5 µg/dL); (iv) monolateral adrenal tumor with 
unequivocal radiological features of benignity on an 
unenhanced CT scan performed within 4  weeks prior 
to enrollment (size <4 cm, regular shape and margins, 
homogeneous density <10 HU); ECOG Performance Status 
≤2. Effective contraception was required, but hormonal 
contraceptives were not allowed. Exclusion criteria were 
prior treatment with metyrapone or any drug specifically 
directed against cortisol excess, adrenal tumor of uncertain 
origin (suspicious for malignancy), known hereditary 
syndrome (Carney’s syndrome, McCune–Albright 
syndrome, MEN-1), any severe concomitant disease 
or impairment of organ function that may prevent the 
participation in the study procedures, pregnancy, breast-
feeding, history of alcohol or drug abuse, history of recent 
or active malignancy, acute or chronic uncontrolled 
infections, non-collaborating patient. The study was 
designed in agreement with the Declaration of Helsinki 
and was approved by the Ethics Committee of San Luigi 
Gonzaga Hospital (‘Comitato Etico Interaziendale A.O.U. 
San Luigi Gonzaga’). The clinical trial was registered in 
the European Clinical Trial database (EudraCT number: 
2013-002063-26). The patients volunteered for the study 
and gave their written informed consent. The study 
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is reported according to the Transparent Reporting of 
Evaluations with Nonrandomized Designs (TREND) (10). 
The flow chart in Fig. 1, as recommended by the TREND 
statement, describes the different phases and design of 
the study.
Study objectives
The aim of our study was the prospective assessment of 
metyrapone as pre-operative treatment.
Primary objective
The primary objective of this study is to assess the efficacy 
of metyrapone in attaining normalization of 24-h urinary 
free cortisol (UFC) excretion or a ≥50% decrease from 
baseline using the mean of 2 UFC measurements within 
3 months of treatment.
Secondary objectives
 • Time to response.
 • Dose–response relationship.
 • Effect of metyrapone on levels of serum cortisol, 
UFC, salivary cortisol, ACTH, 11-deoxycortisol, total 
testosterone, androstenedione, DHEAS in terms of 
percent variation relative to baseline.
 • Improvement of the clinical signs associated to 
hypercortisolism (blood pressure, BMI, waist).
 • Improvement of quality of life, assessed by the CS 
questionnaire.
 • Improvement of the metabolic alterations associated 
to hypercortisolism (fasting hyperglycemia, 
dyslipidemia).
 • Safety and tolerability of oral assumption of 
metyrapone at different doses.
Study protocol
The study was done in an outpatient setting at three 
centers involved in patient recruitment. It consisted in 
two periods: a screening period (up to 2 weeks, from Day 
−14 to Day 0 screening of potentially eligible patients) 
and a treatment period (82 ± 8 days, with scheduled visits 
at Day 7, 14, 31, 48, 65 and 82). The study period included 
24  months of enrolling period (from March 2014 to 
February 2016) and 3  months of treatment period (last 
scheduled visits in May 2016).
During treatment period, all patients received from 
investigators the same oral metyrapone formulation 
(metyrapone 250 mg, tablets, provided by HRA Pharma, 
Paris, France), at the initial dose of 250 mg thrice daily 
with further titration (up or down-titration) at scheduled 
times on individual basis according to hormone levels, 
clinical features and patient’s tolerance. Compliance for 
study drug has been assessed by counting capsules at 
the scheduled patient visits. Patients have been asked to 
record the date and time of dosing and number of study 
drug capsules taken. Adherence to the study protocol will 
be reinforced at each visit and during the weekly contact 
(telephone or email).
Figure 1
Flow chart indicating the different phases of the 
study to week four as recommended by the 
TREND statement (10). Subjects 1 and 2 
discontinued treatment for a few days due to 
nausea, fatigue and low-grade fever.
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The metyrapone efficacy was monitored by UFC 
levels. The current dose of metyrapone should have been 
continued in case of normalization of UFC. If UFC was 
not normalized, the dose should have been up titrated 
by 250 mg per day, at each scheduled visit. The possible 
development of hypoadrenalism was monitored by the 
evaluation of serum cortisol levels. In case of cortisol 
levels (before metyrapone intake) <248 nmol/L (<9 µg/dL), 
metyrapone should have been reduced by at least 250 mg.
A complete physical examination (including general 
appearance, HEENT (head, eyes, ears, nose, throat), as well as 
dermatologic, cardiovascular, respiratory, gastrointestinal, 
extremities/musculoskeletal and neurologic body system) 
was performed at screening and at each scheduled visit. 
Vital signs including blood pressure, heart rate, respiratory 
rate and oral body temperature have been collected. 
Weight and waist circumference have been measured at 
baseline and during each visit with the same scales and 
tape measures, respectively, to ensure consistency. Twelve-
lead ECG tracings have been obtained in triplicate from 
all patients. Blood samples for biochemical test (glycemic 
and lipid profile, electrolytes) were obtained at screening 
and at each visit. For hypertensive and diabetic patients, 
number of specific drugs and daily doses were recorded. 
An endocrine work-up was required at screening and at 
predefined evaluation points (Days 14, 31, 48, 65, 82). 
Blood samples for hormone measurement (serum cortisol, 
ACTH, total testosterone, androstenedione, DHEAS, 
11-deoxycortisol) were obtained between 08:00 h and 
09:00 h before the morning metyrapone dose, while UFC 
excretion was measured on a daily urine collection (UFC 
reference range <165 nmol/24 h, corresponding to the 
95th percentile value of a reference population of normal 
subjects). Salivary cortisol was evaluated collecting salivary 
samples thrice daily at 08:00, 16:00, 23:00 h, immediately 
before each metyrapone dose, by chewing a cylindrical 
cotton swab (Salivette, Sarstedt, Nümbrecht, Germany) 
for about 2 min. The subjects were told not to eat and 
brush their teeth since at least 3 h before the collection. 
Samples were centrifuged at 1500 g for 3 min, the cotton 
swab was removed, and the collected saliva samples were 
frozen at −20°C until assayed.
Hormone measurements were centralized in a reference 
laboratory (Laboratorio di tossicologia, Fondazione IRCCS 
Ca’ Granda, Ospedale Maggiore Policlinico Milano). 
Results of serum and urinary cortisol measurements were 
available within 3 days to allow for prompt dose titration 
of metyrapone.
The performance status of all patients was graded 
according to the ECOG Performance Status scale and the 
toxicity associated with study drug was rated using the 
NCI CTCAE v 4.0 (11). Presence of symptoms of cortisol 
excess was annotated and judged by the investigator by 
using the specific Cushing questionnaire (12). Patients 
were steadily monitored throughout the study for the 
occurrence of adverse events. All adverse events occurring 
from the beginning of the study and up to 30 days after 
the end of the administration of the drug were recorded, 
regardless of the potential relationship to the study drug. 
The date of onset, severity, seriousness and investigator’s 
opinion of potential relationship of the event to study 
drug were recorded.
Hormone measurements
Steroids in serum
To analyze cortisol, 11-deoxycortisol, DHEAS, testosterone 
and androstenedione levels by LC–MS/MS, an IVD-MS 
steroids serum kit (MassChrom, Steroids in Serum/
Plasma, Chromsystems, Gräfelfing, Germany) was used. 
Chromatographic separation and mass spectrometry 
of the samples was performed with a high-performance 
liquid chromatography (HPLC, Shimadzu, Milano, Italy) 
interfaced with a Sciex 4500 MD mass spectrometer 
(Sciex, Milano, Italy). Samples were prepared according to 
the manufacturer’s instructions.
Salivary and urinary cortisol
The determination of both salivary and urinary cortisol 
was carried out in the presence of cortisol-d4 as deuterated 
internal standard, by LC–MS/MS after submitting the 
saliva and urine sample to a purification by an online 
TurboFlow system (Thermo Scientific), using a Cyclone 
column (50 mm length, 0.5 mm internal diameter, Thermo 
Scientific), as previously described (13). Cortisol was 
separated in liquid chromatography using a C18 reversed-
phase column (Hypersil Gold, 50 mm length, 2.1 mm 
internal diameter, 3 µm particle size, Thermo Scientific), 
with a gradient of aqueous ammonium formate (5 mM) 
with 0.1% formic acid and methanol as eluent, flowing at 
0.7 mL/min. Detection and quantification were performed 
by a triple quadrupole mass spectrometer (TSQ Quantum 
Access, Thermo Scientific) equipped with a heated-electro 
spray ionization source (H-ESI), operating in the positive 
ion mode. The method for detecting salivary cortisol had 
a precision, assessed as percent coefficient of variation, of 
less than 5%, accuracy between 99 and 102% and a limit 
of quantification (LOQ) of 1 nmol/L. The throughput was 
about 100 samples/day. The method for detecting UFC had 
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a precision, assessed as percent coefficient of variation, of 
less than 10%, accuracy between 98 and 107% and a limit 
of quantification (LOQ) of 3 nmol/L.
Plasma ACTH levels
Plasma ACTH levels (pmol/L) were measured by 
chemiluminescent immunometric assay (Immulite 2000, 
Siemens Medical Solutions Diagnostics) with an inter-
assay coefficient of variation ranged from 6.1 to 10.0%, 
an intra-assay coefficient of variation ranged from 6.7 and 
9.5% and sensitivity of 1 pmol/L.
Statistical analysis
This is a pilot study and no formal power calculation has 
been performed.
This study is exploratory in nature. All statistical 
analyses were performed as intention to treat with 
descriptive and exploratory purposes and the results of 
statistical tests presented with CIs. Data were collected by 
means of an eCRF and centralized to the Unit of San Luigi 
Hospital for further processing. All statistical analyses 
were performed with Statistica (StatSoft) statistical 
software. The Mann–Whitney non-parametric test will be 
used for analysis of continuous variables, the chi-square 
test will be used for nominal or ordinal explanatory and 
response variables. Correlation analyses were determined 
by calculating the Spearman’s R coefficient. P values of 
less than 0.05 were considered to indicate statistical 
significance. Rates and proportions were calculated 
for categorical data and medians and ranges for 
continuous data.
Results
Baseline characteristics of the patients are provided in 
Table  1. At baseline, 4/7 patients had mild-to-moderate 
hypercortisolism and the remaining had severe 
hypercortisolism. All patients completed the treatment 
period and the median daily doses of metyrapone were 
as follows: 750 mg at Day 14, 750 mg at Day 31 (range 
500–1250 mg), 1000 mg at Day 48 (250–1750 mg), 
750 mg at Day 65 (250–1750 mg) and 750 mg at Day 82 
(250–1750 mg). At baseline, UFC levels were 609 nmol/24 h 
(188–1476 nmol/24 h) and they decreased in all patients 
from Day 0 to Day 82 (Fig. 2). In the overall group, the 
median percentage change in UFC level comparing to 
baseline was −76.0% (range −88.4% to +55.3%; P = 0.05) 
after 2  weeks and −84.5% (range −97.8% to +31.9%; 
P < 0.03) after 1  month of treatment, respectively. 
Normalization of UFC level was reported in all patients at 
Day 65 (85 nmol/24 h, range 36–128 nmol/24 h), and Day 
82 (69 nmol/24 h, range 28–152 nmol/24 h), with median 
percentage change comparing to baseline of −90.1% 
(range −94.1% to −46.7%; P < 0.02) and −88.7% (range 
−96.6% to −56.6%; P < 0.02), respectively. Also serum and 
salivary cortisol levels progressively decreased from Day 0 
to Day 82. At the end of the treatment period, the median 
Table 1 Baseline characteristics of patients.
Characteristic Patients (n = 7)
Age (years)
 Median 40
 Range 30–66
Sex (N)
 Men 2
 Women 5
Time since diagnosis (months)
 Median 2
 Range 1–7
Size of adenoma (mm)
 Median 30
 Range 24–31
Hypertension (N)
 Yes 5
 No 2
Diabetes mellitus (N)
 Yes 1
 No 6
Severity of hypercortisolism (N)
 Mild 2
 Moderate 2
 Severe 3
Mild hypercortisolism = UFC level <2 times the upper limit of the normal 
range (ULN); moderate hypercortisolism = UFC level between 2 and 5 
times the ULN; severe hypercortisolism = UFC level >5 times the ULN.
Figure 2
UFC levels at Day 0 and Day 82 in seven patients treated with 
metyrapone. 165 nmol/24 h is the upper limit of the reference range.
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percentage change in morning serum cortisol was −35.2% 
(range −73.5% to +9.7%; P < 0.05), while the median 
percentage change in salivary cortisol was −63.0% (range 
−73.2% to +8.6%; P = 0.06) at 08:00 h, −66.9% (range 
−83.9% to −13.6%; P < 0.04) at 16:00 h, and −79.8% 
(range −91.2% to −55.2%; P < 0.02) at 23:00 h, respectively 
(Table  2). During the treatment period, median plasma 
ACTH and serum DHEAS did not increase significantly 
(Table 2). Serum testosterone and serum androstenedione 
levels significantly increased in women, although values 
were in the normal range (Table  2). In all patients 
serum 11-β-deoxycortisol levels significantly increased 
from Day 0 to Day 82 (Table  2). During the treatment, 
an improvement in the quality of life and pressure was 
observed (Table  3). The median changes from Day 0 to 
Day 82 were as follows: health-related quality of life score, 
+16.7 points (range +4.2 to +52.00, P < 0.04); systolic 
blood pressure, −25 mmHg (range −52 to −10 mmHg, 
P < 0.01); diastolic blood pressure, −16 mmHg (range 
−50 to +2 mmHg, P < 0.03). Moreover, 3/7 patients were 
able to reduce the number of anti-hypertensive drugs. 
No significant change in weight, waist circumference, 
glycemic profile and lipid profile was reported (Table 3). 
During treatment, sodium and potassium levels were in 
the normal range.
There were no deaths or serious adverse events during 
treatment and metyrapone was well tolerated by all 
subjects. All drug-related adverse events were grade 1 or 2, 
and generally transient. The reported drug-related effects 
include nausea, fatigue, low grade fever (in 2/7 patients), 
Table 2 Hormonal characteristics of patients.
Characteristic Day 0 Day 82 P Value
UFC (nmol/24 h)
 Median (range) 609 (188–1476) 69 (28–152) 0.017
 Reference range 12–165
Serum morning cortisol (nmol/L)
 Median (range) 599 (392–665) 306 (174–715) 0.047
 Reference range 138–690
Salivary cortisol h 08:00 (nmol/L)
 Median (range) 21 (6–39) 6 (6–14) 0.062
 Reference range 1–15
Salivary cortisol h 16:00 (nmol/L)
 Median (range) 16 (3–36) 4 (2–15) 0.032
 Reference range 1–5
Salivary cortisol h 23:00 (nmol/L)
 Median (range) 14 (5–32) 2 (1–14) 0.016
 Reference range 1–3
ACTH (pmol/L)
 Median (range) 1 (1–2) 1 (1–11) 0.42
 Reference range 1–10
Testosterone in men (nmol/L)
 Median (range) 3 (3–4) 8 (4–12) 0.43
 Reference range 9–35
Testosterone in women (nmol/L)
 Median (range) 1 2 (1–3) 0.033
 Reference range 1–3
Androstenedione in men (nmol/L)
 Median (range) 1 2 (1–2) 0.13
 Reference range 2–9
Androstenedione in women (nmol/L)
 Median (range) 1 (1–10) 7 (3–12) 0.014
 Reference range 2–9
11-β-Deoxycortisol (nmol/L)
 Median (range) 2 (1–4) 69 (4–92) 0.017
 Reference range 1–9
DHEAS (µmol/L)
 Median (range) 1 (1–8) 1 (1–8) 0.44
 Reference range <17 (M)
<14 (childbearing age)
<3 (menopausal age)
For all variables, there were seven valid cases. Bold text indicates statistically significant values. 
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which resolved after discontinuing treatment for a few days 
and re-introducing a lower dose (250 mg less); lower limb 
edema (2/7 patients), which resolved with introduction 
of 50–100 mg spironolactone; transient facial rash (in 2/7 
patients). Hirsutism and acne were not reported in female 
patients, and in one case, an improvement of hirsutism 
and menstrual periodicity was reported.
Discussion
We did a prospective, open-label, pilot study involving 
a pre-operative treatment with metyrapone in seven 
patients with ACTH-independent CS due to adrenal 
adenoma scheduled for adrenalectomy. The rationale of 
this study is that patients with adrenal adenoma should 
be the best candidates to benefit from metyrapone because 
they may lack a compensatory rise of ACTH secretion 
during treatment, since ACTH is chronically suppressed by 
autonomous cortisol secretion. This could ameliorate the 
safety profile of metyrapone, avoiding side effects caused 
by an ACTH-mediated increase of steroid precursors with 
weak mineralocorticoid activity (increased blood pressure, 
edema and hypokalemia) or androgen effects (hirsutism, 
acne, irregular menstrual cycles). The medical need of a 
pre-operative course of metyrapone is in the possibility 
to control a severe Cushing, thus reducing associated 
morbidity that increases operative risks and complications. 
Moreover, an effective medical treatment of cortisol excess 
that provides useful palliation of Cushing stigmata, thus 
improving clinical conditions, quality of life and avoiding 
incoming complications, is useful even in mild-moderate 
Cushing whether a long time lag between diagnosis and 
surgery is expected. As a matter of fact, patients with CS 
should be referred to high-volume expert surgical centers, 
which in Italy have usually long waiting lists for benign 
conditions.
Whether it is known that metyrapone may control 
rapidly cortisol excess in 50–75% of patients with CS due 
to different causes (4), only data collected retrospectively 
are available to prove the efficacy of metyrapone. This is to 
our knowledge the first prospective study on metyrapone 
use in CS. Moreover, there is limited available information 
on the outcome of metyrapone treatment in patients 
with ACTH-independent CS. Verhelst and colleagues (8) 
observed an effective reduction of serum cortisol levels 
Table 3 Clinical and biochemical characteristics of patients.
Characteristic Day 0 Day 82 P Value
Glycemia (mmol/L)
 Median (range) 5.6 (4.4–8.2) 4.9 (4.4–6.1) 0.15
 Reference range 4.0–5.5
HOMA index
 Median (range) 2.7 (2.2–8.8) 2.7 (1.1–3.9) 0.27
Total cholesterol (mmol/L)
 Median (range) 5.7 (4.4–5.8) 5.2 (4.2–6.1) 0.22
 Reference range <5.2
Triglycerides (mmol/L)
 Median (range) 1.2 (0.4–2.9) 1.3 (0.4–2.6) 0.89
 Reference range <1.7
BMI (kg/m2)
 Median (range) 27.1 (23.3–35.8) 26.1 (22.8–36.9) 1.00
Waist circumference (cm)
 Median (range) 90 (88–125) 91 (87–126) 0.88
HrQoL score
 Median (range) 39.8 (22.9–68.7) 65.6 (27.1–92) <0.03
SBP (mmHg)
 Median (range) 140 (120–180) 128 (110–130) <0.01
DBP (mmHg)
 Median (range) 96 (85–124) 80 (70–98) <0.03
Sodium (mmol/L)
 Median (range) 139 (136–142) 139 (138–145) 0.46
 Reference range 136–145
Potassium (mmol/L)
 Median (range) 4.0 (3.1–4.8) 4.1 (3.8–4.4) 0.46
 Reference range 3.6–5.2
For all variables, there were seven valid cases. Bold text indicates statistically significant values.
BMI, body mass index; DBP, diastolic blood pressure; HRQoL, health-related quality of life; SBP, systolic blood pressure.
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in 13/16 patients with cortisol-secreting adrenal tumors 
(10 adrenal adenoma, 6 adrenocortical carcinoma) treated 
with a median daily dose of 1750 mg (range 750–6000). 
Daniel and colleagues (9) reported 124 patients treated 
with metyrapone monotherapy before any surgical 
intervention, including 25 benign adrenal disease and 
7 adrenocortical carcinoma (ACC), for an average of 
4.0 months. In this group, control of daily cortisol levels 
was achieved in 50% of patients with available data, while 
control of UFC levels was found in 35% of patients with 
available data. The median daily start dose of metyrapone 
was 750 mg (range 500–2250) in patients with benign 
adrenal disease, and 1500 mg (750–2000) in patients with 
ACC, while the median daily final dose was 1000 mg 
(500–4000) and 1000 mg (750–1500), respectively.
Our findings demonstrate a prompt and effective 
activity of metyrapone also in patients with severe 
hypercortisolism, who showed a UFC reduction greater 
than 80% after 2 weeks of treatment. Most of our patients 
(5/7) achieved UFC normalization after 1  month of 
treatment and the normalization of UFC was found in 
all patients at the end of the treatment period (Day 82). 
The median final dose of metyrapone in our study was 
of 750 mg daily (range 250–1500 mg), lower than that in 
other reported series (8, 9). This is likely due to differences 
in study design (retrospective series vs a prospective study) 
and included patients (patients with benign adrenal 
disease or ACC in previous series vs patients with adrenal 
adenoma in our study).
Normalization of UFC was accompanied by reduction 
in serum and salivary cortisol, and marked clinical 
improvement. Scores for health-related quality of life 
increased, and we observed a significant drop in systolic 
and diastolic blood pressure. The prompt and remarkable 
effect on blood pressure outlines the tight link between 
hypercortisolism and hypertension (14, 15, 16, 17, 
18, 19, 20). Improvement in blood pressure occurred 
despite the expected rise of 11-desoxycortisol, a cortisol 
precursor with weak mineralocorticoid activity, due to the 
metyrapone-induced inhibition of the CYP11B1 (21, 22, 
23). However, this might have contributed to lower limb 
edema in two patients, which resolved with 50–100 mg of 
spironolactone.
Interestingly, we did not observe a compensatory 
increase in ACTH secretion (21); ACTH remained below 
limits of detection in four patients and increased into 
the normal range in the remainders. Moreover, we find 
only a moderate increase in androgens with no clinical 
effect; conversely, a female patient reported amelioration 
of hirsutism and menstrual periodicity, probably due to 
the beneficial effect of cortisol reduction. This would 
confirm our hypothesis that the lack of ACTH rise due to 
the chronic pituitary suppression in patients with ACTH-
independent CS limited the shift toward the androgen 
pathway. Verhelst et al. in a retrospective study evaluated 
ACTH patterns in patients with adrenal-dependent CS 
on metyrapone and did not find any significant ACTH 
increase in ten patients with adrenal adenoma and six 
patients with adrenal carcinoma (8). Instead ACTH levels 
were not reported by Daniel et al. (9).
The post-operative follow-up was heterogeneous 
among the different centers and we have incomplete 
information. After adrenalectomy, all patients received 
glucocorticoid replacement therapy (cortisone acetate). 
At 6–12  months after adrenalectomy, all patients had 
normal blood pressure (median systolic blood pressure, 
115 mmHg, 105–120; median diastolic blood pressure, 
80 mmHg, 70–85).
To summarize, we have demonstrated for the first 
time the activity of metyrapone in a prospective series 
of patients with adrenal-dependent CS. We are aware 
of the limitations of our study due to the small number 
of patients, but we think that our results support the 
feasibility of a short-lived treatment with metyrapone 
before adrenal surgery. We have shown that metyrapone 
is able to normalize cortisol excess rapidly, thus leading 
to a remarkable improvement of patient conditions, and 
this makes the drug perfectly suitable for a pre-operative 
use. We have also shown that a short-lived treatment has 
a very favorable safety profile in patients with adrenal-
dependent CS, due to either the condition of ACTH 
independency or the limited duration of treatment. Since 
our patient characteristics represent the average patient 
with overt CS due to an adrenal adenoma, we think that 
our results are generalizable to this patient population.
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